Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model

Journal of Alzheimer's Disease

Volumn 5, Issue 4, 2003, Pages 301-308

  Pérez, Mar ^a   Hernández, Félix ^a   Lim, Filip ^a   Díaz Nido, Javier ^a   Avila, Jesús ^a  

^a CSIC   (Spain)

Author keywords

Alzheimer's disease; Glycogen synthase kinase 3; Lithium; Neurodegeneration; Protein aggregation; Tauopathy

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; LITHIUM; TAU PROTEIN;

ARTICLE; CHROMOSOME 17; DEGENERATIVE DISEASE; ENZYME INHIBITION; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; MISSENSE MUTATION; MOUSE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; TAUOPATHY; TRANSGENIC MOUSE;

EID: 0242720372     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2003-5405     Document Type: Article

References (41)

1. A. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal and K. Iqbal, Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments, Proc Natl Acad Sci USA 98 (2001), 6923-6928.
2. G. Alvarez, J.R. Munoz-Montano, J. Satrustegui, J. Avila, E. Bogonez and J. Diaz-Nido, Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration, FEBS Lett 453 (1999), 260-264.
3. G. Alvarez, J.R. Munoz-Montano, J. Satrustegui, J. Avila, E. Bogonez and J. Diaz-Nido, Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease, Bipolar Disord 4 (2002), 153-165.
4. M. Arrasate, M. Perez, R. Armas-Portela and J. Avila, Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations, FEBS Lett 446 (1999), 199-202.
5. J. Avila, Tau aggregation into fibrillar polymers: taupathies, FEBS Lett 476 (2000), 89-92.
6. V. Buee-Scherrer, O. Condamines, C. Mourton-Gilles, R. Jakes, M. Goedert, B. Pau and A. Delacourte, AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease, Brain Res Mol Brain Res 39 (1996), 79-88.
7. R. Castellani, K. Hirai, G. Aliev, K.L. Drew, A. Nunomura, A. Takeda, A.D. Cash, M.E. Obrenovich, G. Perry and M.A. Smith, Role of mitochondrial dysfunction in Alzheimer's disease, J Neurosci Res 70 (2002), 357-360.
8. R.W. Chen and D.M. Chuang, Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity, J Biol Chem 274 (1999), 6039-6042.
9. D.M. Chuang, R.W. Chen, E. Chalecka-Franaszek, M. Ren, R. Hashimoto, V. Senatorov, H. Kanai, C. Hough, T. Hiroi and P. Leeds, Neuroprotective effects of lithium in cultured cells and animal models of diseases, Bipolar Disord 4 (2002), 129-136.
10. N.L. Daly, R. Hoffmann, L. Otvos, Jr. and D.J. Craik, Role of phosphorylation in the conformation of tau peptides implicated in Alzheimer's disease, Biochemistry 39 (2000), 9039-9046.
11. T.C. Gamblin, M.E. King, H. Dawson, M.P. Vitek, J. Kuret, R.W. Berry and L.I. Binder, In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants, Biochemistry 39 (2000), 6136-6144.
12. M. Goedert, R. Jakes and R.A. Crowther, Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments, FEBS Lett 450 (1999), 306-311.
13. M. Goedert, R. Jakes, R.A. Crowther, P. Cohen, E. Vanmechelen, M. Vandermeeren and P. Cras, Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein, Biochem J 301 (1994), 871-877.
14. M. Goedert, R. Jakes, Z. Qi, J.H. Wang and P. Cohen, Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase, J Neurochem 65 (1995), 2804-2807.
15. M. Goedert, S. Satumtira, R. Jakes, M.J. Smith, C. Kamibayashi, C.L. White, 3rd and E. Sontag, Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations, J Neurochem 75 (2000), 2155-2162.
16. M. Goedert and M.G. Spillantini, Tau gene mutations and neurodegeneration, Biochem Soc Symp (2001), 59-71.
17. A. Gomez-Ramos, J. Diaz-Nido, M.A. Smith, G. Perry and J. Avila, Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells, J Neurosci Res 1571(6) (March 2003), 863-870.
18. J. Gotz, F. Chen, J. van Dorpe and R.M. Nitsch, Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils, Science 293 (2001), 1491-1495.
19. I. Grundke-Iqbal, K. Iqbal, Y.C. Tung, M. Quinlan, H.M. Wisniewski and L.I. Binder, Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology, Proc Natl Acad Sci USA 83 (1986), 4913-4917.
20. M. Hasegawa, M.J. Smith and M. Goedert, Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly, FEBS Lett 437 (1998), 207-210.
21. M. Hong, V. Zhukareva, V. Vogelsberg-Ragaglia, Z. Wszolek, L. Reed, B.I. Miller, D.H. Geschwind, T.D. Bird, D. McKeel, A. Goate, J.C. Morris, K.C. Wilhelmsen, G.D. Schellenberg, J.Q. Trojanowski and V.M. Lee, Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17, Science 282 (1998), 1914-1917.
22. G.A. Jicha, E. Lane, I. Vincent, L. Otvos, Jr., R. Hoffmann and P. Davies, A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease, J Neurochem 69 (1997), 2087-2095.
23. T.D. King, G.N. Bijur and R.S. Jope, Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium, Brain Res 919 (2001), 106-114.
24. K.S. Kosik, Alzheimer's disease: a cell biological perspective, Science 256 (1992), 780-783.
25. V.M. Lee, Biomedicine. Tauists and beta-aptists united-well almost! Science 293 (2001), 1446-1447.
26. V.M. Lee, M. Goedert and J.Q. Trojanowski, Neurodegenerative tauopathies, Annu Rev Neurosci 24 (2001), 1121-1159.
27. F. Lim, F. Hernandez, J.J. Lucas, P. Gomez-Ramos, M.A. Moran and J. Avila, FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain, Mol Cell Neurosci 18 (2001), 702-714.
28. H.K. Manji, G.J. Moore and G. Chen, Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46 (1999), 929-940.
29. S.E. Merrick, D.C. Demoise and V.M.Y. Lee, Site-specific dephosphorylation of tau protein at Ser(202)/Thr(205) in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A, J Biol Chem 271 (1996), 5589-5594.
30. G.J. Moore, J.M. Bebchuk, K. Hasanat, G. Chen, N. Seraji-Bozorgzad, I.B. Wilds, M.W. Faulk, S. Koch, D.A. Glitz, L. Jolkovsky and H.K. Manji, Lithium increases N-acetylaspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 48 (2000), 1-8.
31. G.J. Moore, J.M. Bebchuk, I.B. Wilds, G. Chen, H.K. Manji and H.K. Menji, Lithium-induced increase in human brain grey matter, Lancet 356 (2000), 1241-1242.
32. J.R. Munoz-Montano, F. Lim, F.J. Moreno, J. Avila and J. Diaz-Nido, Glycogen Synthase Kinase-3 Modulates Neurite Outgrowth in Cultured Neurons: Possible Implications for Neurite Pathology in Alzheimer's Disease, J Alzheimers Dis 1 (1999), 361-378.
33. J.R. Munoz-Montano, F.J. Moreno, J. Avila and J. Diaz-Nido, Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons, FEBS Lett 411 (1997), 183-188.
34. M. Novak, R. Jakes, P.C. Edwards, C. Milstein and C.M. Wischik, Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51, Proc Natl Acad Sci USA 88 (1991), 5837-5841.
35. M. Perez, R. Cuadros, M.A. Smith, G. Perry and J. Avila, Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal, FEBS Lett 486 (2000), 270-274.
36. M. Perez, F. Hernandez, A. Gomez-Ramos, M. Smith, G. Perry and J. Avila, Formation of aberrant phosphotau fibrillar polymers in neural cultured cells, Eur J Biochem 269 (2002), 1484-1489.
37. M. Perez, F. Lim, M. Arrasate and J. Avila, The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules, J Neurochem 74 (2000), 2583-2589.
38. M. Pérez, J.M. Valpuesta, E.M. de Garcini, C. Quintana, M. Arrasate, J.L. López Carrascosa, A. Rabano, J. García de Yebenes and J. Avila, Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy, Am. J. Pathol. 152 (1998), 1531-1539.
39. N. Sahara, J. Lewis, M. DeTure, E. McGowan, D.W. Dickson, M. Hutton and S.H. Yen, Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility, J Neurochem 83 (2002), 1498-1508.
40. M.J. Smith, R.A. Crowther and M. Goedert, The natural osmolyte trimethylamine N-oxide (TMAO) restores the ability of mutant tau to promote microtubule assembly, FEBS Lett 484 (2000), 265-270.
41. H. Wei, P.R. Leeds, Y. Qian, W. Wei, R. Chen and D. Chuang, beta-amyloid peptide-induced death of PC 12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment, Eur J Pharmacol 392 (2000), 117-123.